Revolution Medicines Company Insiders
| RVMD Stock | USD 54.10 4.42 8.90% |
Revolution Medicines employs about 700 people. The company is managed by 12 executives with a total tenure of roughly 1634 years, averaging almost 136.0 years of service per executive, having 58.33 employees per reported executive. Evaluation of Revolution Medicines' management performance can provide insight into the firm performance.
Revolution | Build AI portfolio with Revolution Stock |
Revolution Medicines Management Team Effectiveness
The company has return on total asset (ROA) of (0.2647) % which means that it has lost $0.2647 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4661) %, meaning that it created substantial loss on money invested by shareholders. Revolution Medicines' management efficiency ratios could be used to measure how well Revolution Medicines manages its routine affairs as well as how well it operates its assets and liabilities.Revolution Medicines Workforce Comparison
Revolution Medicines is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 19,429. Revolution Medicines holds roughly 700 in number of employees claiming about 4% of equities under Health Care industry.
Revolution Medicines Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Revolution Medicines insiders, such as employees or executives, is commonly permitted as long as it does not rely on Revolution Medicines' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Revolution Medicines insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Revolution Medicines Notable Stakeholders
A Revolution Medicines stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Revolution Medicines often face trade-offs trying to please all of them. Revolution Medicines' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Revolution Medicines' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mark Goldsmith | President CEO | Profile | |
| Jeff JD | General VP | Profile | |
| David Pompliano | Founding Officer | Profile | |
| Jack Anders | Chief Officer | Profile | |
| Erin Graves | Senior Relations | Profile | |
| Walter Reiher | Chief Officer | Profile | |
| Path FRCP | Pres RD | Profile | |
| Margaret JD | Chief Officer | Profile | |
| Michael Fischbach | Academic Board | Profile | |
| Xiaolin Wang | Executive Development | Profile | |
| Kevan Shokat | Academic Board | Profile | |
| Jan Smith | Chief Officer | Profile |
About Revolution Medicines Management Performance
The success or failure of an entity such as Revolution Medicines often depends on how effective the management is. Revolution Medicines management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Revolution management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Revolution management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Revolution Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 212 people.
Please note, the presentation of Revolution Medicines' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Revolution Medicines' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Revolution Medicines' management manipulating its earnings.
Revolution Medicines Workforce Analysis
Traditionally, organizations such as Revolution Medicines use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Revolution Medicines within its industry.Revolution Medicines Manpower Efficiency
Return on Revolution Medicines Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 857.3K | |
| Net Loss Per Executive | 50M | |
| Working Capital Per Employee | 3.1M | |
| Working Capital Per Executive | 180.3M |
Complementary Tools for Revolution Stock analysis
When running Revolution Medicines' price analysis, check to measure Revolution Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines is operating at the current time. Most of Revolution Medicines' value examination focuses on studying past and present price action to predict the probability of Revolution Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines' price. Additionally, you may evaluate how the addition of Revolution Medicines to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |